Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Brief Summary: This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.


Options:
A: Arm Label: Tocilizumab 162 mg sc; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab 162 mg | Arm Label: Placebo sc; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tocilizumab 162 mg; Assigned to Arm(s): Tocilizumab 162 mg sc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo sc
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Group I: 2mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group II: 2mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group III: 4mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group IV: 4mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group V: IV Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group II: 2mg/kg Golimumab only, Group III: 4mg/kg Golimumab + MTX, Group IV: 4mg/kg Golimumab only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group III: 4mg/kg Golimumab + MTX, Group V: IV Placebo + MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group II: 2mg/kg Golimumab only, Group IV: 4mg/kg Golimumab only, Group V: IV Placebo + MTX
D: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A